VermaSLeiterLAManglaKK, et al.Epidemiology and burden of peripheral artery disease in people with type 2 diabetes: A systematic literature review. Diabetes Ther. 2024;15(9):1893-1961.
2.
BeckmanJADuncanMSDamrauerSM, et al.Microvascular disease, peripheral artery disease, and amputation. Circulation. 2019;140(6):449-458.
3.
FowkesFGAboyansVFowkesFJ, et al.Peripheral artery disease: Epidemiology and global perspectives. Nat Rev Cardiol. 2017;14(3):156-170.
4.
CriquiMHMatsushitaKAboyansV, et al.Lower extremity peripheral artery disease: Contemporary epidemiology, management gaps, and future directions: A scientific statement from the American Heart Association. Circulation. 2021;144(9):e171-e191. doi:10.1161/CIR.0000000000001005
5.
MazzolaiLTeixido-TuraGLanziS, et al.2024 ESC guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024;45(36):3538-3700.
6.
GornikHLAronowHDGoodneyPP, et al.2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(24):e1313-e1410. doi:10.1161/CIR.0000000000001251
7.
StevensJWSimpsonEHarnanS, et al.Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg. 2012;99(12):1630-1638.
8.
KalantziKTentolourisNMelidonisAJ, et al.Efficacy and safety of adjunctive cilostazol to clopidogrel-treated diabetic patients with symptomatic lower extremity artery disease in the prevention of ischemic vascular events. J Am Heart Assoc. 2021;10(1):e018184.
9.
SogaYIidaOHiranoK, et al.Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol. Catheter Cardiovasc Interv. 2012;79(4):541-548.
10.
FassoraMCalancaLJaquesCMazzolaiLKayserBLanziS. Intensity-dependent effects of exercise therapy on walking performance and aerobic fitness in symptomatic patients with lower-extremity peripheral artery disease: A systematic review and meta-analysis. Vasc Med. 2022;27(2):158-170.
11.
DaviesMJArodaVRCollinsBS, et al.Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925-1966.
12.
SattarNLeeMMYKristensenSL, et al.Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653-662.
13.
PerkovicVTuttleKRRossingP, et al.Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109-121.
14.
LincoffAMBrown-FrandsenKColhounHM, et al.Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232.
15.
NauckMAQuastDRWefersJMeierJJ. GLP-1 receptor agonists in the treatment of type 2 diabetes—state-of-the-art. Mol Metab. 2021;46(10):1102.
16.
GouveriEPopovicDSPapanasN. Potential new therapeutic implications of semaglutide: New colours of the rainbow?Diabetes Ther. 2024;15(1):13-18.
17.
PantazopoulosDGouveriEPapiMPapazoglouDPapanasN. GLP-1 receptor agonists, DPP-4 inhibitors and the skin-diabetes meets dermatology: A brief narrative review. Adv Ther. 2025;42(8):3621-3633.
18.
MehdiSFPusapatiSAnwarMS, et al.Glucagon-like peptide-1: A multi-faceted anti-inflammatory agent. Front Immunol. 2023;14:1148209.
19.
DhatariyaKBainSCBuseJB, et al.The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: Results from the LEADER trial. Diabetes Care. 2018;41(10):2229-2235.
20.
BrevettiGGiuglianoGBrevettiLHiattWR. Inflammation in peripheral artery disease. Circulation. 2010;122(18):1862-1875.
21.
BonacaMPCatarigAMHoulindK, et al.Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): A phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025;405(10489):1580-1593.
22.
KarakasisPPatouliasDFragakisNMantzorosCS. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism. 2025;164:156113.
MarsoSPDanielsGHBrown-FrandsenK, et al.Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322.
25.
RerkasemASripanPPongtamS, et al.The prevalence and risk factors for peripheral arterial disease in adults living with human immunodeficiency virus. Int J Low Extrem Wounds. 2023;22(2):332-338.
26.
RerkasemAMangklabruksABuranapinS, et al.Chronic kidney disease predicts adverse major cardiovascular events and adverse limb events in patients with diabetes and peripheral arterial disease. Int J Low Extrem Wounds. 2024;23(1):19-26.
27.
RerkasemANopparatkailasRNantakoolS, et alThe ability of clinical decision rules to detect peripheral arterial disease: A narrative review. Int J Low Extrem Wounds. 2025;24(2):273-282.
